EHJ - Cardiovascular Pharmacotherapy
Focusing on clinical cardiovascular pharmacology
Showing 24 of 875 results
ESC Journals
ESC Journals
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
28 July 2026
ESC Journals
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence
17 July 2026
ESC Journals
Treatment effects in contemporary cardiovascular pharmacotherapy: determinants and interpretation
14 July 2026
ESC Journals
The anticoagulation dilemma in post-operative atrial fibrillation after cardiac surgery
7 July 2026
ESC Journals
ESC Journals
ESC Journals
Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation
23 June 2026
ESC Journals
Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
17 June 2026
ESC Journals
Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study
16 June 2026
ESC Journals
Beta-blockers after myocardial infarction: indication, ejection fraction, and de-escalation pathway
13 June 2026
ESC Journals
Longitudinal loop diuretic use in patients with HFrEF initiated with sodium–glucose cotransporter 2 inhibitors
10 June 2026
ESC Journals
Venous vascular pharmacology: how does it contribute to heart failure with preserved ejection fraction?
29 May 2026
ESC Journals
ESC Journals
ESC Journals
Kidney function and acid–base status as gatekeepers of natriuretic and diuretic responsiveness in chronic HF: insights from the DEA-HF clinical trial
18 May 2026
ESC Journals
Correction to: Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus
18 May 2026
ESC Journals
Selective serotonin reuptake inhibitors and bleeding risk in patients undergoing PCI on dual antiplatelet therapy: a retrospective cohort study
15 May 2026
ESC Journals
Management of dyslipidaemia in patients with comorbidities—facing the challenge: heart failure
7 May 2026
ESC Journals
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study
7 May 2026
ESC Journals
Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with drug coated balloons in acute coronary syndromes: insights from the SWEDEHEART registry
7 May 2026
ESC Journals
Effect of intensive blood pressure and blood glucose control on cardiovascular outcomes driven by reductions in cardiovascular death and nephropathy: win ratio analysis of ADVANCE trial
29 April 2026
ESC Journals
Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study
28 April 2026
ESC Journals
From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not ‘one-and-done’
28 April 2026
